Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Goy, R. Sinha, Michael Williams, S. Beşışık, J. Drach, R. Ramchandren, Lei Zhang, S. Cicero, T. Fu, T. Witzig (2013)
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 29
M. Fridrik, A. Petzer, F. Keil, W. Willenbacher, U. Jaeger, A. Lang, S. Burgstaller, J. Andel, O. Krieger, W. Oberaigner, R. Greil (2011)
Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized TrialBlood, 118
B. Oiffier, E. Epage, J. Rière, R. Erbrecht, T. Illy, R. Ouabdallah, P. Ierre, M. Orel, E. Este, G. Alles, P. Aulard, F. Eyes, C. Isselbrecht (2002)
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaThe New England Journal of Medicine, 346
F. d'Amore, S. Leppä, Maria Silva, T. Relander, P. Brown, E. Weidmann, G. Lauritzsen, A. Pezzutto, A. Hoof, M. Gelder, J. Doorduijn, K. Wu, J. Kluin-Nelemans, P. Lugtenburg, M. Jankovska, M. Merup, U. Fagerli, J. Walewski, H. Hagberg, J. Mariz, P. Hansen, T. Noesslinger, A. Janssens, L. Brandefors, H. Demuynck, M. Schaafsma, I. Christiansen, D. Šálek, S. Jyrkkiö, V. Procházka, J. Zijlstra, L. Bohmer, R. Greil, W. Stevens, R. Fijnheer, M. Kooy, M. Grube, G. Hopfinger, E. Neste, E. Jantunen, L. Truemper, G. Wulf, B. Altmann, M. Ziepert, M. Loeffler, Helle Toldbod (2012)
First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose TherapyBlood, 120
Michael Wang, S. Rule, P. Martin, A. Goy, R. Auer, B. Kahl, W. Jurczak, R. Advani, J. Romaguera, J. Mcgreivy, F. Clow, M. Stevens-Brogan, L. Kunkel, K. Blum (2012)
Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-upBlood, 120
L. Swinnen, Hailun Li, A. Quon, R. Gascoyne, E. Ranheim, T. Habermann, R. Advani, B. Kahl, S. Horning (2012)
Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404)Blood, 120
W. Wilson, J. Gerecitano, A. Goy, S. Vos, V. Kenkre, P. Barr, K. Blum, A. Shustov, R. Advani, J. Lih, Mickey Williams, R. Schmitz, Yandan Yang, S. Pittaluga, George Wright, L. Kunkel, J. Mcgreivy, S. Balasubramanian, M. Cheng, D. Moussa, J. Buggy, L. Staudt (2012)
The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 StudyBlood, 120
B. Kahl, Hailun Li, Mitchell Smith, R. Gascoyne, David Yang, E. Paietta, R. Advani, S. Horning (2012)
Mature Results From ECOG Study E1405 – A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell LymphomaBlood, 120
M. Fridrik, H. Hausmaninger, W. Linkesch, M. Stöger, H. Sill, M. Neubauer, H. Seewann, J. Klocker, R. Haidinger, L. Schiller, J. Pont, G. Raudaschl, M. Falk, T. Radaszkiewicz (1996)
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 1
A. Chiappella, S. Franceschetti, A. Castellino, A. Carella, I. Baldi, M. Zanni, A. Liberati, M. Spina, C. Bottelli, V. Pavone, A. Molinari, P. Zinzani, F. Salvi, P. Fattori, A. Zaccaria, B. Botto, A. Congiu, M. Ladetto, M. Dreyling, G. Gaidano, G. Rossi, U. Vitolo (2012)
Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)Blood, 120
M. Fanale, A. Shustov, A. Forero-Torres, N. Bartlett, R. Advani, B. Pro, Robert Chen, A. Davies, T. Illidge, D. Kennedy, S. Horwitz (2012)
Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell LymphomasBlood, 120
G. Nowakowski, B. Laplant, C. Reeder, J. Foran, L. Porrata, W. Macon, P. Johnston, C. Rivera, T. Habermann, D. Inwards, I. Micallef, G. Nelson, S. Ansell, T. Witzig (2012)
Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II StudyBlood, 120
C. Récher, B. Coiffier, C. Haioun, T. Molina, C. Fermé, O. Casasnovas, C. Thieblemont, A. Bosly, G. Laurent, F. Morschhauser, H. Ghesquières, F. Jardin, S. Bologna, C. Fruchart, B. Corront, J. Gabarre, C. Bonnet, M. Janvier, D. Canioni, J. Jais, G. Salles, H. Tilly (2011)
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trialThe Lancet, 378
A. Goy, R. Sinha, Michael Williams, S. Beşışık, J. Drach, R. Ramchandren, M. Robertson, I. Avivi, J. Rowe, R. Herbrecht, A. Hoof, M. Egyed, Lei Zhang, S. Cicero, T. Fu, T. Witzig (2012)
Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” StudyBlood, 120
M. Pfreundschuh, L. Trümper, A. Osterborg, R. Pettengell, M. Trněný, K. Imrie, D. Ma, D. Gill, J. Walewski, P. Zinzani, R. Stahel, S. Kvaløy, O. Shpilberg, U. Jaeger, M. Hansen, T. Lehtinen, A. López-Guillermo, C. Corrado, A. Scheliga, N. Milpied, M. Mendila, M. Rashford, E. Kuhnt, M. Loeffler (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.The Lancet. Oncology, 7 5
Recent clinical data presented at the annual meeting of the American Society of Hematology underline the importance of incorporating cytarabine in the induction treatment of younger patients with mantle cell lymphoma, while other trials confirmed the importance of immuno-chemotherapy with rituximab and bendamustine, especially in elderly patients. R-CHOP remains the standard for first line treatment in diffuse large B-cell lymphoma, though, several new therapeutic agents such as lenalidomide and ibrutinib are now tested in clinical trials as single agent or in combination with established therapies. Finally, some new therapeutic options for the unfavorable subset of T-cell lymphoma were presented.
memo - Magazine of European Medical Oncology – Springer Journals
Published: Jun 18, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.